Sanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.31, EUR0.53 better than the analyst estimate of EUR0.78. Revenue for the quarter came in at EUR10.56 billion versus the consensus estimate of EUR12.38 billion.

OUTLOOK

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)

For earnings history and earnings-related data on Sanofi (SNY) click here.